Leukeran is one of 229 small molecule programs targeting Leukemia. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
181 competitors in Gastric Cancer
Leukeran
Taxol
Opdivo
Camptosar
Keytruda
Xeloda
Platinol
Taxotere
Abraxane
Avastin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jan 1, 1982
LEUKERAN
NDA NDA010669
Sources
Details